Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1205772 | 0.91 | C5AR1 (0.39) | C5AR1ADORA1 | |
| SCHEMBL1205735 | 0.90 | C5AR1 (0.40) | C5AR1ADORA1 | |
| SCHEMBL12879076 | 0.89 | C5AR1 (0.38) | C5AR1LMNAMEN1ALDH1A1GAA | |
| SCHEMBL18329486 | 0.88 | C5AR1 (0.37) | C5AR1 | |
| SCHEMBL12879079 | 0.88 | C5AR1 (0.37) | C5AR1ALDH1A1 | |
| SCHEMBL12879077 | 0.87 | C5AR1 (0.37) | C5AR1MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL12879080 | 0.87 | C5AR1 (0.37) | C5AR1LMNAMEN1ALDH1A1GAA | |
| SCHEMBL14522074 | 0.87 | MEN1 (0.34) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL19305375 | 0.86 | C5AR1 (0.36) | C5AR1 | |
| SCHEMBL1206356 | 0.86 | SMN1; SMN2 (0.37) | C5AR1MEN1ALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979356-B1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER PROD INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-7884117-B2 | Protein kinase inhibitors such as (S)-2-(methylamino)-1-phenylethyl 3-(4-fluorobenzamido)-6,6-dimethylpyrrolo[3,4-c]pyrazole-5(1H,4H,6H)-carboxylate, used for the treatment of abnormal cell growth in mammals; antiproliferative agents | PFIZER INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884117-B2 | Protein kinase inhibitors such as (S)-2-(methylamino)-1-phenylethyl 3-(4-fluorobenzamido)-6,6-dimethylpyrrolo[3,4-c]pyrazole-5(1H,4H,6H)-carboxylate, used for the treatment of abnormal cell growth in mammals; antiproliferative agents | PFIZER INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884117-B2 | Protein kinase inhibitors such as (S)-2-(methylamino)-1-phenylethyl 3-(4-fluorobenzamido)-6,6-dimethylpyrrolo[3,4-c]pyrazole-5(1H,4H,6H)-carboxylate, used for the treatment of abnormal cell growth in mammals; antiproliferative agents | PFIZER INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20090318440-A1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318440-A1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318440-A1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318440-A1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PAK4, PAK5, PAK3 | C5AR1 3945/4885LMNA 3611/4885MEN1 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.